Esketamine hydrochloride

Phase 3Small molecule

TThe Second Hospital of Anhui Medical University

Esketamine hydrochloride is one of 225 small molecule programs targeting Cardiac Arrest. It is currently in Phase 3.

Indications

Total Trials

Active Trials

224

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiac ArrestRecruiting

Rett SyndromeActive, not recruiting

Major Depressive DisorderRecruiting

SchizophreniaActive, not recruiting

TonsillectomyRecruiting

Laparoscopic Sleeve GastrectomyUnknown status

Efficacy and SafetyNot yet recruiting

EndometriosisRecruiting

Treatment Resistant DepressionRecruiting

Cardiac ArrestPhase 2

Recruiting

Rett SyndromePhase 1

Active, not recruiting

Major Depressive DisorderPhase 3

Recruiting

SchizophreniaPreclinical

Active, not recruiting

TonsillectomyPhase 3

Recruiting

Laparoscopic Sleeve GastrectomyPreclinical

Unknown status

Efficacy and SafetyPhase 3

Not yet recruiting

EndometriosisPhase 3

Recruiting

Treatment Resistant DepressionPhase 3

Recruiting

Competition

Competitive Landscape

228 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

11 2

Venclexta

AbbVie

Phase 3

9 3

Savaysa

Daiichi Sankyo

Phase 3

3 4

Dacogen

Sun Pharmaceutical Industries, Inc.

Phase 3

3 5

Imfinzi

AstraZeneca

Phase 3

1 6

Fludara

Sanofi

Phase 3

1 7

Cytoxan

BBaxter Healthcare Corporation

Phase 3

5 8

Taxotere

AAvyxa

Phase 3

4 9

Tuoyi

SSun Yat-sen University

Phase 3

4 10

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Treatment Resistant Depression

NCT07369102

Post-ApprovalNot yet recruiting

Efficacy and Safety

NCT07063108

Q3 2027

Phase 2Recruiting

Cardiac Arrest

NCT06744361

Q2 2028

Phase 3Recruiting

Major Depressive Disorder

NCT05603104

Phase 3Recruiting

Major Depressive Disorder

NCT05973851

Clinical

Trials by Indication[1]

Major Depressive Disorder2 trials

Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

Recruiting·—·Phase 3·NCT05603104·1,254 enrolled

The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Recruiting·—·Phase 3·NCT05973851·418 enrolled

Esketamine2 trials

Pharmacokinetics and Pharmacodynamics of Nasally Applied Esketamine

Completed·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT00847418

Effects of Esketamine Combined With Propofol for Sedation on Systemic Inflammation and Immune Function in Septic Patients in the ICU: a Single-center, Non-blind, Prospective Randomized Controlled Trial

Terminated·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Approved·NCT04843982·10 enrolled

Endometriosis1 trial

Esketamine as Treatment for Chronic Pain Due to Endometriosis: a RCT Study

Recruiting·RReinier de Graaf Groep·Phase 3·NCT06161805·56 enrolled

Laparoscopic Sleeve Gastrectomy1 trial

Effect of Esketamine on Depressive Symptoms of Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy

Unknown status·TThe Second Hospital of Anhui Medical University·N/A·NCT06199011·400 enrolled

Schizophrenia1 trial

Network Dysfunction, Schizophrenia and Pharmacological Magnetic Resonance Imaging (phMRI)

Completed·MMedical University of Vienna·N/A·NCT01394757·52 enrolled

6 more indications

Tonsillectomy1 trial

Effects of Esketamine on Postoperative Behavioral Changes in Children Undergoing Tonsillectomy and/or Adenoidectomy

Recruiting·FFujian Provincial Hospital·Phase 4·NCT06579937·172 enrolled

Complication1 trial

To Investigate the Effect of Esketamine Hydrochloride on Pulmonary Complications

Recruiting·ZZhang XIao Mei·Phase 4·NCT06467513·102 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of S-ketamine in Elderly Patients Undergoing Non-cardiac Surgery: a RCT（ESSENCE）

Not yet recruiting·—·Phase 4·NCT07063108·276 enrolled

Cardiac Arrest1 trial

Ketamine Sedation As Neuroprotective Agent Following Out-of-hospital Cardiac Arrest

Recruiting·CChristian Hassager·Phase 2·NCT06744361·282 enrolled

Treatment Resistant Depression1 trial

Esketamine With or Without Integration Therapy for Treatment-Resistant Depression

Recruiting·UUniversity of Puerto Rico·Phase 4·NCT07369102·20 enrolled

Rett syndrome1 trial

Esketamine for the Treatment of Rett Syndrome

Active, not recruiting·—·Phase 1·NCT06199700·3 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Esketamine hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Esketamine hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Esketamine hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Second Hospital of Anhui Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TThe Second Hospital of Anhui Medical University

Esketamine hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q2 2028

Trials by Indication[1]

Major Depressive Disorder2 trials

Esketamine2 trials

Endometriosis1 trial

Laparoscopic Sleeve Gastrectomy1 trial

Schizophrenia1 trial

Tonsillectomy1 trial

Complication1 trial

Efficacy and Safety1 trial

Cardiac Arrest1 trial

Treatment Resistant Depression1 trial

Rett syndrome1 trial

References

Drug Info

Quick Facts

Related News